Follow The Filings

WGS GeneDx

GeneDx earnings company data as of 7:49 PM ET 10/23

Scheduled

1 period, newest first, nothing reported yet. Each row shows EPS above revenue.

Period Date Metric Estimate Actual Result
FY2026 Q3 27 Oct EPS 0.07 — —
Rev — — —

Insider trades

Open-market buys and sales by WGS's executives, directors and 10% owners in the last 12 months, from their Form 4s

All WGS insider trades
  • $107M bought by 2 insiders
  • $6.1M sold by 1 insider outside a trading plan
  • $511K sold by 1 insider under 10b5-1 plans
  1. Casdin Capital, LLC Director, +3 joint filers
    Buy
    $11.1M 200,000 shares at $55.55 +5.7% to stake
    Traded Jun 4–5 Filed Jun 8
  2. Casdin Capital, LLC Director, +3 joint filers
    Buy
    $21.5M 500,000 shares at $42.92 +17% to stake
    Traded May 18–20 Filed May 20
  3. Keith A. Meister Director, +1 joint filer
    Buy
    $13.8M 351,273 shares at $39.19 +7.9% to stake
    Traded May 13–15 Filed May 15
  4. Keith A. Meister Director, +1 joint filer
    Buy
    $46.8M 1,205,147 shares at $38.84 +37% to stake
    Traded May 7–11 Filed May 11
  5. Keith A. Meister Director, +1 joint filer
    Buy
    $13.5M 169,521 shares at $79.40 +5.5% to stake
    Traded Mar 3–5 Filed Mar 5
  6. Bryan Dechairo COO
    Planned sale
    $511K 5,961 shares at $85.70 100% of stake
    Traded Feb 4 Filed Feb 6
  7. Joshua Ruch Director
    Sale
    $6.1M 38,000 shares at $160.37 24% of stake
    Traded Nov 24, 2025 Filed Nov 26, 2025

Also filed in the last 12 months, not counted as buying or selling: 85 sales to cover taxes, 38 option exercises, and 4 stock grants.

SEC filings

Recent issuer filings from EDGAR, 14 shown.

Filed Form Detail Links
SCHEDULE 13G —
SCHEDULE 13G/A —
8-K 2.02,9.01
10-Q
SCHEDULE 13G —
8-K 5.07
8-K 5.02,7.01,9.01
SCHEDULE 13D/A —
SCHEDULE 13D/A —
SCHEDULE 13D/A —
8-K 2.02,9.01
10-Q
DEF 14A
DEFA14A

Estimates are consensus figures; SEC filings remain the official record. Not investment advice.